Date: 2014-02-04
Type of information: Collaboration agreement
Compound: DTect-All™
Company: Domain Therapeutics (France) Xoma (USA - CA)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism: Domain Therapeutics’ DTect-All™ was specifically designed to successfully work with challenging GPCRs including orphans. It constitutes a unique and proprietary screening technology enabling sensitive detection of compounds binding to the targeted GPCR fused to a fluorescent protein. Detection is made by measuring changes in the Fluorescence Resonance Energy Transfer (FRET) signal that has taken place between the fluorescent protein and a fluorescent probe selected from Domain’s proprietary probe collection. As the FRET-based assays often results in removing the orthosteric binding site, DTect-All™ selectively identifies allosteric modulators.Domain Therapeutics’ DTect-All™ was specifically designed to successfully work with challenging GPCRs including orphans. It constitutes a unique and proprietary screening technology enabling sensitive detection of compounds binding to the targeted GPCR fused to a fluorescent protein. Detection is made by measuring changes in the Fluorescence Resonance Energy Transfer (FRET) signal that has taken place between the fluorescent protein and a fluorescent probe selected from Domain’s proprietary probe collection. As the FRET-based assays often results in removing the orthosteric binding site, DTect-All™ selectively identifies allosteric modulators.
Disease:
Details: * On February 4, 2014, Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), has announced it has entered into a multi-step collaboration with Xoma, a U.S. public company focusing its research on allosteric modulation which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. Domain Therapeutics operates DTect-All™, a platform that has successfully discovered small molecule allosteric modulators for a wide range of GPCRs. Domain Therapeutics and Xoma will jointly evaluate the robustness of this platform to identify allosteric modulator antibodies of a first target. If successful, the partners may elect to further collaborate on other GPCRs from a set of preselected targets for which, under the terms of the agreement, Domain Therapeutics will be eligible for an upfront payment and certain undisclosed milestones per target, as well as undisclosed royalties. Domain will have the right to offer its DTect-All™ platform to discover antibody-based drugs to other companies outside the scope of the set of GPCRs selected by Xoma.
Financial terms:
Latest news:
